Human Genome Sciences Inc. (HGSI) (1 Viewer)
- Creatore Discussione acqua+
- Data di Inizio
DickSIM
Prima o poi....ci becco!
coxy
coxy
per ora le mutande...........
secondo te il modello unno versione antiproiettile non è sufficiente?
DickSIM
Prima o poi....ci becco!
per ora le mutande...........
secondo te il modello unno versione antiproiettile non è sufficiente?
forse posson bastare------
ma sai che è meglio prevenire...che curare!
DickSIM
Prima o poi....ci becco!
siamo pare sotto attacco SHORT! 
Human Genome Sciences (HGSI) experienced a flurry of put volume last Friday. Traders on the International Securities Exchange (ISE) bought to open 3,082 puts during the course of the session, compared to just 224 calls. In other words, puts were approximately 14 times more popular than their bullish counterparts.
In fact, HGSI's puts have rarely been in greater demand on the ISE. The equity's 10-day ISE put/call volume ratio of 0.66 ranks higher than 81.2% of other such readings taken during the past year.
Most of Friday's activity was focused on HGSI's in-the-money July 5 put, where 4,067 contracts crossed the tape on open interest of 16. Most of these puts traded at or near the ask price, suggesting that traders on Friday were initiating new bearish bets on HGSI. This strike now carries 4,004 contracts, establishing it as the site of peak put open interest for July.
The day's bearish bias might have been inspired by a downgrade, as ThinkEquity on Friday cut HGSI from "accumulate" to "source of funds." The stock's weak technical performance might have also prompted a rush for puts -- currently, the shares are pulling back after being rejected last week at their 50-week moving average.
Human Genome Sciences (HGSI) experienced a flurry of put volume last Friday. Traders on the International Securities Exchange (ISE) bought to open 3,082 puts during the course of the session, compared to just 224 calls. In other words, puts were approximately 14 times more popular than their bullish counterparts.
In fact, HGSI's puts have rarely been in greater demand on the ISE. The equity's 10-day ISE put/call volume ratio of 0.66 ranks higher than 81.2% of other such readings taken during the past year.
Most of Friday's activity was focused on HGSI's in-the-money July 5 put, where 4,067 contracts crossed the tape on open interest of 16. Most of these puts traded at or near the ask price, suggesting that traders on Friday were initiating new bearish bets on HGSI. This strike now carries 4,004 contracts, establishing it as the site of peak put open interest for July.
The day's bearish bias might have been inspired by a downgrade, as ThinkEquity on Friday cut HGSI from "accumulate" to "source of funds." The stock's weak technical performance might have also prompted a rush for puts -- currently, the shares are pulling back after being rejected last week at their 50-week moving average.
DickSIM
Prima o poi....ci becco!
ROCKVILLE, Md., June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $33.0 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.
In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria in the long-term treatment of type 2 diabetes mellitus. All inquiries regarding the Phase 2 data presented at ADA, or about the development of Syncria, should be directed to the contacts provided by GSK. To view the GSK press release, please click here.
For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company's web site at www.hgsi.com.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. (Nasdaq: HGSI)
http://news.prnewswire.com/DisplayR...STORY=/www/story/06-08-2009/0005040292&EDATE=
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )
Syncria is a biological product generated from the genetic fusion of human albumin and modified human GLP-1 peptide, and is designed to act throughout the body to help maintain normal blood-sugar levels and to control appetite. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $33.0 million received to date - in addition to single-digit royalties on worldwide sales if Syncria is commercialized.
In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria in the long-term treatment of type 2 diabetes mellitus. All inquiries regarding the Phase 2 data presented at ADA, or about the development of Syncria, should be directed to the contacts provided by GSK. To view the GSK press release, please click here.
For more information about HGS, please direct inquiries to the HGS contacts provided, or visit the Company's web site at www.hgsi.com.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc. (Nasdaq: HGSI)
http://news.prnewswire.com/DisplayR...STORY=/www/story/06-08-2009/0005040292&EDATE=
Netzach
Forumer storico
Venerdì ho provato ad entrare a 2,7$ senza riuscirci, oggi ho provato a 2,6$ e non ce l'ho fatta per un pelo, ce la farò domani?
Pure io ...
coxy
coxy
mi sembra che il sentiment per il biotech in USA sia molto forte.
personalmente non sono ancora pronto con HGSI.
good night